Embryos

Here's some information from Dwarkesh Patel on the topic of embryos:

1. Genomic Prediction in Embryos:

   • Genomic prediction companies have a significant first-mover advantage due to their relationships with clinics and accumulated data. This advantage might not be solely based on who has the best algorithms but also on these business connections and a trusted track record with clinics around the world. Steve Hsu mentions that while companies like 23ANDME might have more data, their specific expertise and technologies in genomic prediction for embryos set them apart 1.

2. Genetic Selection and the FDA:

   • The approval of polygenic scores for embryo selection in the U.S. by the FDA seems challenging. While testing for genetic diseases might be considered safe and potentially broadening the scope of what constitutes a genetic disease could be feasible, selecting embryos for traits like height (e.g., for NBA-qualified children) would be much harder to get approved. Dwarkesh points out that China's government is more open to genetic research and manipulations, citing Yao Ming as an example of the benefits of such genetic selection 2.

These clips illustrate the complexities and ethical considerations of embryo selection and genomic prediction.